1. D. Kritchevsky, “The use of pharmacologic agents in atherosclerosis therapy,” Ann. N.Y. Acad. of Sciences, 149, 1058–1068 (1968).
2. P. Bianchini, “Lipid regulating activity of a duodenal mucosa heparinoid,” in S. Garattini and R. Paoletti, eds., Drugs Affecting Lipid Metabolism, Elsevier Pub. Co. 1961.
3. G. Benedetti, F. Mazza and G. Ferretti, “Esperienze Terapeutiche con un nuovo eparinoide antiaterogeno ad azione chairificante del plasma e non anticoagulante,” Rass. Fisiopat. Clin. Ter. 1 (1959).
4. F. Nicrosini and O. Piccinelli, “Modificazioni della lipemia totale e delle varie frazioni lipidiche indotte da un eparinoide estratto dalla mucosa duodenale,” G. Clin. Med. 40, 3 (1959).
5. S. Thunell, C. A. Antonopoulos and S. Gardell, “Analysis of aortic glycosaminoglycans from various animal species by CPC-cellulose column procedures,” J. Atheroscler. Res. 7, 283–294 (1967).